Clinical Trials Browser

Phase 1/2 × Active not recruiting × cemiplimab × Clear all

NCT05882734 2026-05-28

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT06162572 2026-05-11

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03491683 2026-05-04

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2 Active not recruiting

Glioblastoma

NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Carcinoma, Merkel Cell

NCT04305795 2025-06-19

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04706715 2025-05-31

LAG3 PET Imaging in Advanced Solid Tumors

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Neoplasms

NCT05662397 2025-02-04

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Phase 1/2 Active not recruiting

Neoplasms, Recurrence

NCT03294083 2022-10-27

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell, Neoplasms